News
PulmoBioMed completes Seed Investment Round
We are delighted to announce that we have completed our first investment round with the support of Mercia Asset Management PLC, SFC Capital, and the contribution of business angels in the USA, EU, and UK.
The 40% oversubscribed round will help us grow our team in Newcastle-Upon-Tyne and bring to the US market PBM-HALE, our non-invasive collector of uncontaminated fluids from the deep lung.
Learn More link: https://www.pharmiweb.com/press-release/2024-02-08/pulmobiomed-aims-to-revolutionise-asthma-diagnosis-with-breakthrough-lung-test-pbm-hale
Our NED Clinical Research is recognised in King’s Birthday Honours.
We are delighted to see our NED Clinical Research Professor Sir Peter J. Barnes FRS, FMedSci Knight Bachelor recognised in the King's Birthday Honours as "the most eminent respiratory physician and scientist in the UK, whose work has transformed the understanding and treatment of #asthma and chronic obstructive lung disease (COPD)". 17/06/2023
A Tech Nation Rising Star!
Competing against hundreds of applications, PulmoBioMed has been selected as a Rising Stars 5.0 North East Tech Nation competition winner! This recognises our company and PBM-HALE technology as one of the most innovative in the region. 08/02/2023
First Top 10 Pharma study starts
Asthma is a term that covers a number of different diseases characterised by wheeze and shortness of breath. Over the past 20 years our understanding of asthma has been revolutionised by research showing the immune response of some patients differs to that of others- and new medicines have been brought to market to effectively treat some of these so-called 'endotypes' of asthma.
A global top 10 pharmaceutical company has engaged a European clinical research group to evaluate if PBM-HALE samples collected from patients with severe eosinophilic asthma can help predict the likelihood of response to treatment with modern medicines. The study is expected to last 2 years and require 120 single use PBM-HALE devices to deliver targeted and untargeted multi-omic biomarkers (RNA-SEQ, cytokine protein levels, microbiota) for patient stratification. 17/10/2022
Professor Peter J Barnes joins PulmoBioMed as a Non-executive Clinical Director
PulmoBioMed are proud to announce that Professor Peter J Barnes has taken the position of non-executive clinical director in PulmoBioMed effective immediately. Professor Barnes FRS FMedSci is the most widely published and cited clinical respiratory scientist world-wide for the past 20 years. He served as the President of the European Respiratory Society and co-authored the global clinical guidelines for COPD and Asthma. He also pioneered exhaled breath research in the early 2000’s and co-authored the technical standards and guidelines for this field. Professor Barnes is also acknowledged as instrumental in delivering proof for, and promoting the adoption of exhaled Nitric Oxide gas as a biomarker of lung inflammation.
Our journey started with our founder watching Professor Barnes’s work in 2004 and asking him why he wasn’t using cascade impactor arrays in his exhaled breath work. Professor Barnes joined PulmoBioMed in 2022 after noticing that our deep lung, fine aerosol microbiota data from healthy volunteers lacked any evidence of Haemophilus, a pathogen suspected to cause many asthma attacks, but almost always present in the nasal/oral swabs of people with, or without asthma. Professor Barnes said “ “I am very impressed by the capabilities of the new PBM-HALE™ device, which is able to detect the virus that causes COVID-19 in the breath for the first time. This device has enormous potential application in diagnosing lung infections and in the diagnosing and monitoring of lung diseases, including asthma and COPD. The ease of collecting breath samples non-invasively means that it can be applied to children and to frail and ill patients”. 15/07/2022
100% detection of symptomatic COVID-19, with just 1 min of breath
We are delighted to announce that preliminary data from our follow up COVID-19 study demonstrates 100% detection of SARS-CoV-2 RNA, the genome of the virus that causes COVID-19, in the exhaled fine aerosols of patients with symptoms. Our friends at the Federal University of Minas Gerais, Brazil, used PBM-HALE to collect breath samples from patients attending a suburban health centre. Participants were included if found COVID-19-positive by routine nasal swab LFT/RAT testing. These breath samples were analysed using the CDC assay. Detection was achieved by asking patients to forcibly exhale into our device. Because PBM-HALE separates saliva droplets from fine aerosols, we can confirm infection in the lung, and quantify virus levels too. Find out more on poster #4515 at the European Respiratory Society conference in Barcelona where you can meet our CEO Pete Hotten.
European Regional Development Fund
PulmoBioMed Ltd is being supported by Innovation SuperNetwork who are the network for innovation support in the North East of England. We will receive funding from the Catalysing Innovation in North East Clusters 2021-2023 project, part of the England European Regional Development Fund and European Structural and Investment Funds Growth Programme 2014-2020.
We are delighted to announce that PulmoBioMed has won the annual BioNOW BioCap Conference pitching competition against stiff competition from 9 other amazing UK medtech / biotech SMEs. Click here to read the BioNow press release. 07/10/2021
WINNERS!
The annual BioCap conference connects life science businesses, researchers and investors across the UK. Join us at this years' virtual event to discuss breath condensate science and hear about PulmoBioMed's vision to transform respiratory medicine by making breath-based diagnostics a reliable alternative to invasive lung sampling. 07/10/2021
PulmoBioMed shortlisted for the annual BioCap pitching competition
Poster presentation at the European Respiratory Society International Congress 2021
Look for abstract no. 3964 in this year's ERS, the leading respiratory medicine conference in Europe, for our work with our colleagues at the University of Ulm on aerosolised virus and nanoparticle capture with PBM-HALE. 25/08/2021
Why does Fractionating Breath Matter?
PulmoBioMed Ltd. present the value of exhaled breath fractionation and condensation to the European Aerosol Society annual conference and discuss the physical means by which PBM-HALE captures deep lung fine aerosol fractions. 25/10/2021
Save the date! Distinguished Prof. Sergey Krylov (York University, Toronto, Canada) has invited our CSO Dr Moschos to present our latest progress update at the York University Toronto Faculty Seminar series. Watch the presentation live on the 2nd June 2021, (12 pm EDT; 7 pm BST; 6 pm UTC) at https://yorku.zoom.us/j/97956630995 19/05/2021
Understanding SARS-CoV-2 airborne transmission: the role of exhaled breath.
Our data on hand-held, non-invasive detection of microorganisms in as few as 5 breaths.
PulmoBioMed can confirm that the PBM-HALE device can efficiently capture aerosolised SARS-CoV-2 in virus like particle format with no loss of particle concentration or size. Our friends at University of Ulm virology have independently reproduced our findings reported earlier in the year. 29/04/2021
PulmoBioMed #ThinkBig
Onyx Health Ltd. announces PulmoBioMed Ltd. as the winners of their Think Big competition.
Take my Breath away: Society for General Microbiology Annual General Conference oral presentation.
Dr John Henderson (Northumbria University) will be presenting his work on Public Health microbiology and the latest update on PBM-HALETM-based detection of exhaled breath condensate and aerosol-vectored micro-organisms, including viruses. Watch the presentation live at 14:45 BST on 03/03/21 or in archival format. 15/04/2021
PulmoBioMed – a new medtech spin-out in the North East of England.
Launched with funding from Northumbria University and Innovate UK, and with its first product PBM-Hale™ in clinical trials in Europe, PulmoBioMed now seeks to close its £2.5 m initial equity capital raise. 08/01/2021
NEW NORTHUMBRIA UNIVERSITY SPINOUT – PULMOBIOMED - TO DEVELOP WORLD-LEADING MEDICAL DEVICE.
Scientists at Northumbria University have worked with the institution’s Research and Innovation Services to launch a medtech spinout company whose lead product for collecting breath samples could revolutionise diagnosis of a range of diseases, including Covid-19. 18/12/2020